We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

51 hedge funds and large institutions have $5.61M invested in Matinas BioPharma in 2023 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

66% more capital invested

Capital invested by funds: $3.37M → $5.61M (+$2.24M)

9% more funds holding

Funds holding: 47 → 51 (+4)

0% less ownership

Funds ownership: 0.24% → 0.24% (-0%)

20% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 10

Holders
51
Holders Change
+4
Holders Change %
+8.51%
% of All Funds
0.74%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
8
Reduced
10
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$127K
2
CCM
Connective Capital Management
California
+$71.7K
3
AWA
Arkadios Wealth Advisors
Georgia
+$50.8K
4
VF
Virtu Financial
New York
+$36.8K
5
Renaissance Technologies
Renaissance Technologies
New York
+$35.5K

Top Sellers

Rank Fund Capital Flow
1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$98.1K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$86.7K
3
Wells Fargo
Wells Fargo
California
-$62.1K
4
SIG
Sargent Investment Group
Maryland
-$23.7K
5
Squarepoint
Squarepoint
New York
-$19.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
SS
26
Simplicity Solutions
Minnesota
$13K – – –
Morgan Stanley
27
Morgan Stanley
New York
$11.9K +$5.64K +500 +83%
Commonwealth Equity Services
28
Commonwealth Equity Services
Massachusetts
$11K +$226 +20 +2%
JP Morgan Chase
29
JP Morgan Chase
New York
$9.81K +$34 +3 +0.3%
NWMG
30
National Wealth Management Group
Ohio
$9.03K -$226 -20 -2%
TRCT
31
Tower Research Capital (TRC)
New York
$8.62K -$1.53K -136 -15%
DAS
32
Dynamic Advisor Solutions
Arizona
$5.93K – – –
TSS
33
Two Sigma Securities
New York
$4.13K +$4.31K +382 New
BCM
34
Bayesian Capital Management
New York
$4.07K +$4.24K +376 New
RPC
35
Rossmore Private Capital
Connecticut
$3.78K – – –
CFG
36
Cooper Financial Group
California
$3.01K – – –
Susquehanna International Group
37
Susquehanna International Group
Pennsylvania
$2.97K +$3.1K +275 New
CG
38
Clarus Group
Texas
$2.59K – – –
JWCA
39
J.W. Cole Advisors
Florida
$2.33K – – –
CFS
40
CRA Financial Services
New Jersey
$2.16K – – –
Osaic Holdings
41
Osaic Holdings
Arizona
$2.16K -$452 -40 -17%
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
$2K -$68 -6 -4%
Fidelity Investments
43
Fidelity Investments
Massachusetts
$757 +$790 +70 New
SPIA
44
Steward Partners Investment Advisory
New York
$657 – – –
EWA
45
EverSource Wealth Advisors
Alabama
$649 – – –
HFM
46
Hartford Financial Management
Connecticut
$541 – – –
ASN
47
Advisory Services Network
Georgia
$432 +$452 +40 New
RIL
48
Rothschild Investment LLC
Illinois
$143 +$147 +13 New
GWMIA
49
Global Wealth Management Investment Advisory
Florida
$141 – – –
IA
50
IFP Advisors
Florida
$139 – – –
1
2
3

MTNB Hedge Fund Activity: Q4 2023 in Review

51 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2023, worth a combined $5.61M — up 66% from $3.37M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new MTNB positions and 6 closed out — a net gain of 4 holders — while 8 added to existing stakes and 10 trimmed.

The largest buyer was Vanguard Group, adding an estimated $127K. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $98.1K sold.

  • 51 institutional investors held Matinas BioPharma (MTNB) as of Q4 2023, up from 47 in Q3 2023.
  • Funds reported $5.61M of Matinas BioPharma stock for Q4 2023, up 66% quarter-over-quarter.
  • 10 funds opened new Matinas BioPharma positions in Q4 2023 and 6 closed out, a net change of +4 holders.
  • The largest Matinas BioPharma buyer in Q4 2023 was Vanguard Group, an estimated $127K added.
  • The largest Matinas BioPharma seller in Q4 2023 was Jacobs Levy Equity Management, an estimated $98.1K sold.

Based on aggregated 13F filings for Q4 2023.